Current Edition

Abzena

Abzena nabs $65M to bolster manufacturing and research services on both sides of the pond

Roughly one year after dropping designs on a $200 million biologics plant in North Carolina, antibody-drug conjugate specialist Abzena has snared a fresh round of …

Continue Reading →
Aduhelm

Biogen’s Aduhelm call to action backfires as CMS receives many more comments in favor of restrictive coverage: analyst

During a January Q&A call with investors, Biogen chief Michel Vounatsos pressed Aduhelm supporters to fight the Centers for Medicare & Medicaid Services’ (CMS’) restrictive …

Continue Reading →
Amgen

Novartis, Amgen settle their dueling lawsuits over migraine drug Aimovig

Novartis and Amgen have spent years arm wrestling one another over their development and commercialization deal on migraine prevention drug Aimovig. Now, the parties appear …

Continue Reading →
AbbVie

Eyeing its post-Humira future, AbbVie angles for broader Rinvoq use in U.S., Europe

Despite classwide safety worries in the U.S., AbbVie is making strides in its quest to build immunology up-and-comer Rinvoq. AbbVie sent off applications to U.S. and …

Continue Reading →
Aspaveli

After its $7.6B buyout fell through, Sobi scores NICE backing for rare disease drug Aspaveli

After rare disease drugmaker Sobi reportedly had a buyout scuppered by pharma giant AstraZeneca, the company has picked up a win that stands to bolster …

Continue Reading →
byproduct

PROSTATE CANCER DRUG BYPRODUCT CAN FUEL CANCER CELLS, UNITED STATES-BASED RESEARCHERS FIND

A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research …

Continue Reading →
clinical

Speeding Drug Development with Clinical Trials in a Dish

The average time to bring a new drug to market is 12 years—assuming it makes it through the rigorous regulatory hurdles. Any technology or methodology …

Continue Reading →
2nd

AstraZeneca won’t submit lung drug for COPD after 2nd study miss

AstraZeneca no longer plans to seek approval of its new respiratory biologic Fasenra in chronic obstructive pulmonary disease (COPD) after the second of two Phase 3 …

Continue Reading →
cancer

Redx Pharma up as it confirms cancer drug clinical trial will re-start early next year

After discussions with the regulator, RXC004 will be administered at a lower initial dose Redx Pharma plc(LON:REDX) shares gained on Wednesday as the group confirmed it will …

Continue Reading →
Asia Pacific

India’s drug regulator expects to finalize new clinical trial rules in two months

India’s drug regulator plans to finalize new rules for clinical trials in a couple of months that would shorten the review time, a senior official …

Continue Reading →